<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2405">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04646239</url>
  </required_header>
  <id_info>
    <org_study_id>202011081</org_study_id>
    <nct_id>NCT04646239</nct_id>
  </id_info>
  <brief_title>Biomarkers of Trained Immunity Following MMR Vaccination</brief_title>
  <official_title>Determining Biomarkers of Trained Immunity in a Randomized Controlled Trial of the Measles, Mumps, and Rubella Vaccine - a Sub-study of the CROWN CORONATION Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a substudy of NCT04333732. The goal of this sub-study is to identify and characterize&#xD;
      biomarkers of trained immunity by measuring, in vitro, immune responses to heterologous&#xD;
      products, especially viral associated products, in the MMR vaccinated compared placebo&#xD;
      groups.&#xD;
&#xD;
      All participants are randomly assigned to MMR or placebo injection at baseline, followed by&#xD;
      SARS-CoV-2 specific vaccination. Blood is drawn around 60 to 90 days after the last&#xD;
      SARS-CoV-2 specific vaccine injection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A sub-study of the CROWN CORONATION Trial (COVID-19 Research Outcomes Worldwide Network for&#xD;
      CORONAvirus prevenTION; NCT04333732). The goal of this sub-study is to identify and&#xD;
      characterize biomarkers of trained immunity by measuring, in vitro, immune responses to&#xD;
      heterologous products, especially virally associated products, in those exposed to MMR&#xD;
      vaccine injection compared to those exposed to 0.9% sodium chloride ('normal saline') placebo&#xD;
      injection.&#xD;
&#xD;
      A secondary objective is comparison of SARS-CoV-2 neutralization assays between MMR and&#xD;
      placebo comparison groups around 60 to 90 days after the last SARS-CoV-2 specific vaccine&#xD;
      injection.&#xD;
&#xD;
      All participants are randomly assigned to MMR or placebo injection at baseline, followed by&#xD;
      SARS-CoV-2 specific vaccination. Blood is drawn around 60 to 90 days after the last&#xD;
      SARS-CoV-2 specific vaccine injection. Peripheral blood mononuclear cells (PMBC) will be&#xD;
      isolated from samples and stimulated with heterologous products (for example; Roswell Park&#xD;
      Memorial Institute medium [RPMI; negative control], MMR [the vaccine itself as specific&#xD;
      stimulus], severe acute respiratory syndrome coronavirus-2 [SARS-CoV-2; heat inactivated],&#xD;
      influenza virus [heat inactivated], toll-like receptor 3 ligand [TLR3 ligand; poly I:C],&#xD;
      toll-like receptor 7/8 ligand [TLR7/8 ligand; R848], toll-like receptor 4 ligand [TLR4&#xD;
      ligand; lipopolysaccharide (LPS)]). Supernatants will be assayed by multiplex luminex protein&#xD;
      assay at 24 hr (for example; type I interferons [IFN], interleukin [IL]-1β , IL-6, tumor&#xD;
      necrosis factor [TNF]-α) and after 5 days (for example; IFN-γ, IL-17, IL-22, IL-10). This&#xD;
      process of testing stimulus-response will be conducted on both the baseline and day 30&#xD;
      samples, collected from both the MMR and Placebo groups.&#xD;
&#xD;
      Neutralization assay will be conducted on all samples using wild-type SARS-CoV-2.&#xD;
&#xD;
      Measles IgG titres will be measured on all samples. Measles IgG titres will be used for&#xD;
      sensitivity analysis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 17, 2020</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cytokine (or chemokine) production in response to heterologous stimuli</measure>
    <time_frame>Around 60 to 90 days after last SARS-CoV-2 specific vaccine injection</time_frame>
    <description>Cytokines such as TNF-α, IL-1β and IL-6 produced by human monocytes, and IFN-γ produced by natural killer (NK)-cells, are markers of trained immunity and these (and other cytokines and chemokines) will be measured in supernatants of stimulated PBMCs from a cohort of participants in the CROWN CORONATION trial. All cytokines and chemokines are measured in picograms/milliliter.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neutralization assay</measure>
    <time_frame>Around 60 to 90 days after last SARS-CoV-2 specific vaccine injection</time_frame>
    <description>Neutralizing antibody activity to wild-type SARS-CoV-2</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Participants in the CROWN CORONATION trial</arm_group_label>
    <description>The CROWN CORONATION trial will randomly allocate adult participants to a single intramuscular injection of MMR vaccine or Placebo (0.9% saline). All participants in this sub-study receive SARS-CoV-2 specific vaccine subsequent to the MMR or Placebo injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Heterologous stimuli</intervention_name>
    <description>In vitro exposure of peripheral blood mononuclear cells to heterologous stimuli</description>
    <arm_group_label>Participants in the CROWN CORONATION trial</arm_group_label>
    <other_name>For example; RPMI medium, MMR, SARS-CoV-2, Influenza, TLR3 ligand, TLR7/8 ligand, TLR4 ligand</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Neutralization assay</intervention_name>
    <description>In vitro measurement of neutralizing antibody activity to wild-type SARS-CoV-2</description>
    <arm_group_label>Participants in the CROWN CORONATION trial</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      45 mL peripheral blood drawn around 60 to 90 days after last SARS-CoV-2 vaccine injection.&#xD;
      De-identified plasma and peripheral blood mononuclear cells will be extracted from the&#xD;
      collected specimens and stored for analysis.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The CROWN CORONATION trial enrolls adults at risk of developing COVID-19 due to their work&#xD;
        in the healthcare environment. To be eligible, prospective participants for the CROWN&#xD;
        CORONATION trial must not have a contra-indication to receiving the live attenuated&#xD;
        Measles, Mumps and Rubella vaccine (MMR) and must not be exposed to agents that may&#xD;
        complicate the interpretation of findings regarding the hypothesized protective effect of&#xD;
        MMR for the prevention of COVID-19. The sub-study will consecutively approach all&#xD;
        participants enrolled in the CROWN CORONATION trial to elicit enrolment in the sub-study&#xD;
        cohort.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion/ Exclusion Criteria:&#xD;
&#xD;
        Prospective participant must already be enrolled into the CROWN CORONATION trial at the&#xD;
        sub-study location. Refer to NCT04333732 for list of inclusion / exclusion criteria for the&#xD;
        study population.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael S Avidan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington Univeristy School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Linda Yun</last_name>
    <phone>314-273-2240</phone>
    <email>lindayun@wustl.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Yun, BS, CCRP</last_name>
      <phone>314-273-2240</phone>
      <email>CrownTrial@email.wustl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Sherry McKinnon, MS, CCRP</last_name>
      <phone>314-286-1768</phone>
      <email>CrownTrial@email.wustl.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Michael S. Avidan, MBBCh, FCASA</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mihai Netea, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shabaana A. Khader, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jonathan Jocum, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Leon du Toit, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anaya Gupta, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Erik Dubberke, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jacco Boon, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hakim-Moulay Dehbi, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>November 20, 2020</study_first_submitted>
  <study_first_submitted_qc>November 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 27, 2020</study_first_posted>
  <last_update_submitted>March 11, 2021</last_update_submitted>
  <last_update_submitted_qc>March 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Washington University School of Medicine</investigator_affiliation>
    <investigator_full_name>Michael Avidan</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>COVID 19</keyword>
  <keyword>Trained Immunity</keyword>
  <keyword>Infectious Diseases</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The project team will make the de-identified data available to the public within 1 year after publication using a public repository. Prior to that time, data will be deposited in the Washington University Open Scholarship repository. Any request for data not deposited in the repository must be directed to the Principal Investigator</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>1 Year</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

